Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

1999266 citationsJournal Articlebronze Open Access

Authors

C.-G. Löfdahl

T.F. Reiss · Merck & Co., Inc., Rahway, NJ, USA (United States)

Jared A. Leff · Merck & Co., Inc., Rahway, NJ, USA (United States)

Elliot Israel · Brigham and Women's Hospital

M.J. Noonan · Allergy Associates Research Center

A. F Finn

Beth C. Seidenberg · Merck & Co., Inc., Rahway, NJ, USA (United States)

Thomas Capizzi

Abstract

Montelukast reduces the need for inhaled corticosteroids among patients requiring moderate to high doses of corticosteroid to maintain asthma control.

Topics & Keywords

Asthma and respiratory diseases Respiratory and Cough-Related Research Inhalation and Respiratory Drug Delivery

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: BMJ

Volume 319, Issue 7202, pp. 87-90

DOI: 10.1136/bmj.319.7202.87

Field-Weighted Citation Impact: 15.02